Skip to main content
. 2005 Jun;49(6):2260–2266. doi: 10.1128/AAC.49.6.2260-2266.2005

TABLE 5.

Microbiological outcomes at TOC visit of ME and MITT patients with MSSA at baseline treated with linezolid or comparator drugsa

Patient population % of patients cured (no. cured/total) after:
Treated with linezolid Randomized to vancomycinb Receiving vancomycin onlyc Switched from vancomycin to alternative antibioticd
ME 84.9 (90/106) 75.3 (70/93) 77.3 (17/22) 74.6 (53/71)
MITT 73 (92/126) 66.4 (75/113) 55.6 (20/36) 71.4 (55/77)
a

TOC visits occured 7 days after the end of treatment.

b

Patients remained on vacomycin or were switched to an alternative antibiotic.

c

Patients remained on vancomycin.

d

Alternative antibiotics specified in the protocol were nafcillin, oxacillin, dicloxacillin, and flucloxacillin.

HHS Vulnerability Disclosure